PDCD1 and cancer: These immune checkpoint inhibitors (ICIs), including pembrolizumab, tislelizumab, nivolumab (anti PD-1) and ipilimumab (anti CTLA-4), have led to dramatic and durable clinical responses in diverse cancers [1].